O Keefe Stevens Advisory Inc. Cuts Position in Perrigo Company plc $PRGO

O Keefe Stevens Advisory Inc. decreased its position in Perrigo Company plc (NYSE:PRGO) by 25.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 167,803 shares of the company’s stock after selling 56,600 shares during the quarter. Perrigo accounts for about 0.6% of O Keefe Stevens Advisory Inc.’s holdings, making the stock its 24th biggest holding. O Keefe Stevens Advisory Inc. owned 0.12% of Perrigo worth $2,336,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the company. Bahl & Gaynor Inc. lifted its holdings in Perrigo by 5.4% during the 3rd quarter. Bahl & Gaynor Inc. now owns 2,087,075 shares of the company’s stock worth $46,479,000 after buying an additional 107,774 shares during the last quarter. Cooke & Bieler LP boosted its position in shares of Perrigo by 11.6% during the 3rd quarter. Cooke & Bieler LP now owns 3,680,411 shares of the company’s stock worth $81,963,000 after acquiring an additional 381,290 shares in the last quarter. Diamond Hill Capital Management Inc. increased its holdings in shares of Perrigo by 8.6% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 1,797,746 shares of the company’s stock valued at $40,036,000 after acquiring an additional 142,363 shares during the last quarter. Nicola Wealth Management LTD. raised its position in shares of Perrigo by 38.4% during the 3rd quarter. Nicola Wealth Management LTD. now owns 281,000 shares of the company’s stock worth $6,257,000 after acquiring an additional 78,000 shares in the last quarter. Finally, BW Gestao de Investimentos Ltda. raised its position in shares of Perrigo by 7.7% during the 3rd quarter. BW Gestao de Investimentos Ltda. now owns 1,582,119 shares of the company’s stock worth $35,234,000 after acquiring an additional 112,595 shares in the last quarter. Hedge funds and other institutional investors own 95.91% of the company’s stock.

Perrigo Trading Down 4.2%

NYSE:PRGO opened at $9.25 on Monday. The company has a market capitalization of $1.27 billion, a PE ratio of -0.90, a P/E/G ratio of 1.09 and a beta of 0.41. Perrigo Company plc has a 52-week low of $9.23 and a 52-week high of $28.43. The stock’s 50 day moving average price is $13.29 and its 200 day moving average price is $16.01. The company has a quick ratio of 1.63, a current ratio of 2.76 and a debt-to-equity ratio of 1.23.

Perrigo (NYSE:PRGO) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.77 earnings per share for the quarter, missing analysts’ consensus estimates of $0.80 by ($0.03). The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Perrigo had a negative net margin of 33.51% and a positive return on equity of 9.41%. Perrigo’s quarterly revenue was down 2.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.93 EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, research analysts anticipate that Perrigo Company plc will post 2.56 EPS for the current year.

Perrigo Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 24th. Investors of record on Monday, March 2nd will be given a $0.29 dividend. The ex-dividend date is Monday, March 2nd. This represents a $1.16 annualized dividend and a yield of 12.5%. Perrigo’s dividend payout ratio is -11.28%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on PRGO shares. Argus raised Perrigo to a “hold” rating in a report on Wednesday, January 14th. Zacks Research raised shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Friday, February 13th. Jefferies Financial Group restated a “hold” rating on shares of Perrigo in a research report on Thursday, February 26th. Canaccord Genuity Group lowered their target price on shares of Perrigo from $20.00 to $17.00 and set a “buy” rating for the company in a report on Friday, February 27th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Perrigo in a research report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $19.33.

Key Stories Impacting Perrigo

Here are the key news stories impacting Perrigo this week:

• Negative Sentiment: Zacks slashed Q1–Q4 2026 and several 2027 quarterly estimates, lowering FY2026 EPS to $2.18 (from $3.00) and FY2027 to $2.53 (from $3.18) — signaling weaker near‑term profit expectations and prompting a “Hold” stance. MarketBeat: Zacks Lowers Perrigo Estimates
• Negative Sentiment: Zacks specifically cut quarterly EPS forecasts across multiple quarters (e.g., Q1 2026 to $0.57 from $0.78; Q2 2026 to $0.45 from $0.63; Q3/Q4 2026 and several 2027 quarters also reduced), increasing the risk that Perrigo will need to re‑accelerate margins or growth to meet consensus. MarketBeat: Zacks Lowers Quarterly Estimates
• Negative Sentiment: Separate coverage summarizing Zacks’ Q2 estimate and commentary reiterated the weaker consensus outlook for near‑term EPS — reinforcing the market’s negative reaction to the downgraded profitability trajectory. Zacks Research Estimates Perrigo’s Q2 Earnings

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.